Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$7.8 million.

  • Maxcyte's Free Cash Flow fell 6172.61% to -$7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.2 million, marking a year-over-year decrease of 9421.49%. This contributed to the annual value of -$29.3 million for FY2024, which is 1526.43% down from last year.
  • As of Q3 2025, Maxcyte's Free Cash Flow stood at -$7.8 million, which was down 6172.61% from -$10.4 million recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Free Cash Flow peaked at $66000.0 during Q4 2023, and registered a low of -$15.1 million during Q1 2025.
  • In the last 5 years, Maxcyte's Free Cash Flow had a median value of -$7.8 million in 2025 and averaged -$7.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 10079.7% in 2023, then tumbled by 1217272.73% in 2024.
  • Quarter analysis of 5 years shows Maxcyte's Free Cash Flow stood at -$2.1 million in 2021, then crashed by 297.66% to -$8.3 million in 2022, then skyrocketed by 100.8% to $66000.0 in 2023, then tumbled by 12172.73% to -$8.0 million in 2024, then increased by 2.64% to -$7.8 million in 2025.
  • Its Free Cash Flow stands at -$7.8 million for Q3 2025, versus -$10.4 million for Q2 2025 and -$15.1 million for Q1 2025.